Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Safety and efficacy of dexmedetomidine for long-term sedation in critically ill patients Ozaki M; Takeda J; Tanaka K; Shiokawa Y; Nishi S; Matsuda K; Doi M; Kakihana Y; Fujino Y; Takinami M; Kawai MJ Anesth 2014[Feb]; 28 (1): 38-50PURPOSE: We evaluated the safety and efficacy of long-term administration of dexmedetomidine in patients in the intensive care unit (ICU). Primary endpoint was the incidence of hypotension, hypertension, and bradycardia. Secondary endpoints were withdrawal symptoms, rebound effects, the duration of sedation with Richmond Agitation-Sedation Scale (RASS) = 0 relative to the total infusion time of dexmedetomidine, and the dose of additional sedatives or analgesics. METHODS: Dexmedetomidine 0.2-0.7 mug/kg/h was continuously infused for maintaining RASS = 0 in patients requiring sedation in the ICU. Safety and efficacy of short-term (= 24 h) and long-term (>24 h) dexmedetomidine administration were compared. RESULTS: Seventy-five surgical and medical ICU patients were administered dexmedetomidine. The incidence of hypotension, hypertension, and bradycardia that occurred after 24 h (long-term) was not significantly different from that occurring within 24 h (short-term) (P = 0.546, 0.513, and 0.486, respectively). Regarding withdrawal symptoms, one event each of hypertension and headache occurred after the end of infusion, but both were mild in severity. Increases of mean arterial blood pressure and heart rate after terminating the infusion of dexmedetomidine were not associated with the increasing duration of its infusion. The ratio of duration with RASS = 0 was >/= 85 % until day 20, except day 9 (70 %) and day 10 (75 %). There was no increase in the dose of additional sedatives or analgesics after the first 24-h treatment period. CONCLUSIONS: Long-term safety of dexmedetomidine compared to its use for 24 h was confirmed. Dexmedetomidine was useful to maintain an adequate sedation level (RASS = 0) during long-term infusion.|Aged[MESH]|Aged, 80 and over[MESH]|Analgesics/*therapeutic use[MESH]|Critical Illness[MESH]|Dexmedetomidine/*administration & dosage/adverse effects[MESH]|Female[MESH]|Heart Rate/drug effects[MESH]|Humans[MESH]|Hypnotics and Sedatives/*administration & dosage/adverse effects[MESH]|Hypotension/epidemiology[MESH]|Intensive Care Units[MESH]|Male[MESH]|Middle Aged[MESH]|Prospective Studies[MESH]|Time Factors[MESH] |